May 9th 2024
Some experts believe offering a subcutaneous version of nivolumab could make PD-1 inhibitors available to new groups of patients who currently lack access, such as those in rural areas.
Contributor: Solving the US Physician Diversity Problem
February 23rd 2022The representation of Black physicians is alarmingly low, but the opportunities for change are possible and urgent. Health care leaders and human resource departments need to address these disparities, and increasing diversity among their workforce is an excellent place to begin.
Read More
Review Outlines Unmet Need for Digital Health in Elderly Patients With MM
February 22nd 2022Access to digital health tools to improve patient outcomes and quality of life are lacking among patients with multiple myeloma (MM) who are elderly, at risk of relapse, or live in rural communities, suggesting more tools and guidelines are needed for these populations.
Read More
Dana-Farber’s Sands: More Lung Screening Would Have Greatest Impact on Cancer Mortality
February 22nd 2022Jacob Sands, MD, who leads the small cell lung cancer research program at Dana-Farber Cancer Institute, speaks with The American Journal of Managed Care (AJMC®) about the need for more patients who meet the criteria for lung screening to catch cancer before it reaches an advanced stage.
Read More
How FGFR Inhibitors Work in Cholangiocarcioma, and What Comes Next
February 21st 2022Drugs targeting FGFR mutations, which are seen in patients with intrahepatic cholangiocarcinoma (CCA), have generated particular excitement; the authors note that prior to the approval of pemigatinib, the first targeted therapy approved by FDA, only 15% to 25% of patients with CCA were “fit enough to receive second-line chemotherapy.”
Read More
Lessons from the early days of chimeric antigen receptor (CAR) T-cell therapy remain fresh as Kite Pharma prepares for the FDA to act on its supplemental biologics license application for use of axi-cel as second-line therapy in relapsed or refractory large B-cell lymphoma. A target action date is set for April 1, 2022.
Read More
Real-world Study Identifies Several Predictors of Risankizumab Response in Psoriasis
February 14th 2022Risankizumab was shown to be highly effective in patients with moderate to severe psoriasis of tertiary medical centers in Italy, in which response was found to be significantly affected by smoking, and incidence of psoriatic arthritis.
Read More
A statement from NCCN’s Advisory Committee on COVID-19 Vaccination and Pre-exposure Prophylaxis said that the panel “endorses vaccination for all eligible persons based on FDA-approved indications or emergency use authorization” and emphasized the need for everyone to be fully vaccinated—including third doses.
Read More
Early Response to Biologics Linked With Stable Long-term Efficacy in Psoriasis
February 12th 2022More patients with moderate-to-severe psoriasis were found to be early responders to ixekizumab vs ustekinumab; all those who achieved early response were associated with stable skin clearance long-term.
Read More
Postsurgery Factors Linked With Disease Control in Chronic Rhinosinusitis With Nasal Polyps
February 8th 2022Patients with chronic rhinosinusitis with nasal polyps who had elevated serum amyloid A (SAA) levels were more likely to achieve disease-controlled status vs those with low SAA levels after endoscopic sinus surgery.
Read More
Payers, Value-based Care Policies Impact Biosimilar Adoption, Cardinal Health Report Finds
February 8th 2022Cardinal Health's report, “2022 Biosimilars Report: The U.S. Journey and Path Ahead,” outlines how biosimilars will move beyond their comfort zones in oncology and rheumatology and more boldly into therapeutic areas such as ophthalmology and diabetes care.
Read More
mRNA COVID-19 Vaccines Safe Among Patients With Cancer History
February 7th 2022A study from investigators at Fox Chase Cancer Center sought comparative outcomes data on adverse reactions from COVID-19 vaccination among patients with a history of cancer and those undergoing treatment and found equivalent safety outcomes.
Read More
Association of Opioid Utilization Management With Prescribing and Overdose
Opioid utilization management in Medicare was associated with mixed effects on opioid prescribing, and prior authorization was associated with a decreased likelihood of subsequent overdose.
Read More
Sinonasal CT Scores May Predict Prognostic Features of Chronic Rhinosinusitis With Nasal Polyps
February 2nd 2022Sinonasal CT scores were associated with several prognostic features in the disease course of chronic rhinosinusitis with nasal polyps, including blood eosinophil counts and risk of relapse after endoscopic sinus surgery.
Read More
Pfizer/BioNTech expected to file for emergency use designation of its COVID-19 vaccine in young children aged 6 months to 5 years; Environmental Protection Agency (EPA) sets limits on power plant emissions of mercury and other hazardous pollutants; Black women at disproportionately greater risk of late-stage cervical cancer diagnosis and death.
Read More